BERLIN and SEATTLE, Oct. 31, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company developing tests based on DNA methylation, today reported financial results for the third quarter of 2007, which ended September 30, 2007.
